Emerging from Johns Hopkins professor Jun O. Liu’s laboratory, Rapafusyn Pharmaceuticals develops non-degrading molecular-glue medicines designed to reach hard-to-drug intracellular and transmembrane targets. Based on its RapaGlue™ platform, the Baltimore biotech is advancing an early pipeline that includes an ENT1 inhibitor for acute kidney injury, an area where the company says no approved preventive therapies exist. Its discovery engine combines AI-enabled machine learning with a DNA-encoded library containing more than 8 billion non-degrading glues.
Generian PharmaceuticalsFormed by UPMC Enterprises, Generian Pharmaceuticals is a Boston- and Pittsburgh-based preclinical biotechnology company developing orally available small-molecule therapeutics for difficult-to-drug diseases often dominated by biologics. Its discovery platform screens proteins in their native cellular environment, then combines target-binding data with disease-relevant phenotypic testing to advance candidates that modulate protein activity, stability, or degradation. The company’s research includes proprietary programs and a collaboration with Astellas for novel targets.
ZyVersa Therapeutics, IncFounded by Stephen C. Glover, ZyVersa Therapeutics is a clinical-stage specialty biopharmaceutical company built around licensed technologies from University of Miami Miller School of Medicine researchers. The company develops medicines for patients with serious inflammatory and renal diseases, with its work centered on unmet medical needs rather than established treatments.WEST CONSHOHOCKEN, PA
Ladder BioFounded in 2020 by Temple University chemist Christian Schafmeister, Ladder Bio is a Blue Bell biotechnology company developing Spiroligomer™ molecules—synthetic, ladder-shaped compounds designed for targeted drug discovery. Its platform combines rational molecular design with libraries containing billions of compounds, pursuing therapeutics and diagnostic applications where conventional small molecules and biologics can fall short. Formerly known as ThirdLaw Molecular, the company has also received more than $16.9 million in non-dilutive funding from the U.S. Department of Defense and the Defense Threat Reduction Agency for biosecurity-related work.325414BLUE BELL, PA
AUM LifeTech, IncPhiladelphia-based AUM LifeTech develops RNA-targeting therapeutics through its proprietary AUM silence antisense oligonucleotide platform, which is designed to silence or regulate disease-linked RNA without an external delivery vehicle. Founded by biotechnology entrepreneur Veenu Aishwarya, the company is pursuing preclinical treatments for genetically defined diseases, including an anti-FOXP3 cancer-immunotherapy program developed with Children’s Hospital of Philadelphia. Its work also includes a Parkinson’s disease program conducted with the University of Pennsylvania.PHILADELPHIA, PA